Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole and Pitavastatin Drug-drug Interaction Study
NCT06808646Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ceftobiprole medocaril (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoints: Maximum Observed Plasma Concentration of Pitavastatin at Day 8, Area Under the Plasma Concentration-time Curve up to Time After Pitavastatin Administration at Day 8 and 1 more. Started Jan 2025; status: completed.
02
Drugs
ceftobiprole medocaril
Beyond the preview
Go deeper on NCT06808646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06808646.